Status:

COMPLETED

Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease

Lead Sponsor:

Cardiovascular Research Society, Greece

Conditions:

Coronary Artery Disease

Atherosclerosis

Eligibility:

All Genders

18-85 years

Brief Summary

Serum NGAL has been described as a biomarker of neutrophil activation and an inflammatory marker which correlates to obesity and its metabolic complications. Since neutrophil activation has been impli...

Detailed Description

Inflammation is considered to play a major role in coronary artery disease (CAD) which accounts for high morbidity and mortality rates in the western world. Several lines of evidence support a role fo...

Eligibility Criteria

Inclusion

  • Consenting patients undergoing coronary angiography due to suspected CAD based on clinical history and results from non-invasive testing

Exclusion

  • Abnormal renal function
  • Any known active inflammatory disease
  • Receiving medical therapy with antibiotics, corticosteroids, immunosuppressive agents

Key Trial Info

Start Date :

September 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2009

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT00749281

Start Date

September 1 2008

End Date

September 1 2009

Last Update

July 8 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Athens Euroclinic

Athens, Attica, Greece, 11521

Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease | DecenTrialz